Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer
<i>KRAS</i> G12C mutation compared to KRAS wild-type did not affect response to chemoradiotherapy, and <i>KRAS</i> mutations compared to <i>KRAS</i> wild-type were not associated with worse survival in unresectable stage II or III NSCLC treated with chemoradiotherapy.
Authors
- S. Deshayes
- S. Thureau (ORCID: https://orcid.org/0000-0001-5772-2336)
- Mathieu Césaire (ORCID: https://orcid.org/0000-0002-8931-000X)
- J. Madelaine
- Dimitri Leite Ferreira
- D. Lerouge
- François Chevalier (ORCID: https://orcid.org/0000-0002-8488-2324)
- Marin Guigo
- Edouard Dantoing
- H. Curcio
- Cathérine Dubos
- Florian Guisier (ORCID: https://orcid.org/0000-0002-8166-7303)
- Pierre Demontrond (ORCID: https://orcid.org/0000-0001-6399-3562)
- Jacques Balosso (ORCID: https://orcid.org/0000-0003-0714-9003)
- François Christy (ORCID: https://orcid.org/0009-0009-1519-8260)
- Radj Gervais
- Kilian Lecrosnier
- Alexandra Leconte
- Pascal Dô
- Jean Cabon (ORCID: https://orcid.org/0009-0004-9933-7996)
- Leonard Jacson
Institutions
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Centre François Baclesse (FR)
- Grand Accélérateur National d'Ions Lourds (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Centre Henri Becquerel
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fonc.2025.1675825
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00